ES2278391T3 - Nuevos inhibidores de anandamida amidasa como agentes analgesicos. - Google Patents

Nuevos inhibidores de anandamida amidasa como agentes analgesicos. Download PDF

Info

Publication number: ES2278391T3
Authority: ES; Spain
Prior art keywords: group; substituted; aryl; heteroaryl; heterocyclyl
Prior art date: 1996-05-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES97927958T

Other languages

English (en)

Spanish (es)

Inventor

Alexandros Makriyannis

Sonyan Lin

William Adam Hill

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Connecticut

Original Assignee

University of Connecticut

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-31

Filing date

1997-05-30

Publication date

2007-08-01

1997-05-30 Application filed by University of Connecticut filed Critical University of Connecticut

2007-08-01 Application granted granted Critical

2007-08-01 Publication of ES2278391T3 publication Critical patent/ES2278391T3/es

2017-05-30 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 title description 38
LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 title description 38
239000003112 inhibitor Substances 0.000 title description 21
239000000730 antalgic agent Substances 0.000 title description 2
-1 hydroxy, hydroxymethyl Chemical group 0.000 claims abstract description 44
150000001875 compounds Chemical class 0.000 claims abstract description 34
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 33
125000000217 alkyl group Chemical group 0.000 claims abstract description 27
125000003118 aryl group Chemical group 0.000 claims abstract description 25
125000000623 heterocyclic group Chemical group 0.000 claims abstract description 24
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 16
241001465754 Metazoa Species 0.000 claims abstract description 15
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 14
108700023418 Amidases Proteins 0.000 claims abstract description 11
102000005922 amidase Human genes 0.000 claims abstract description 11
125000001183 hydrocarbyl group Chemical group 0.000 claims abstract description 11
125000003107 substituted aryl group Chemical group 0.000 claims abstract description 10
239000003814 drug Substances 0.000 claims abstract description 8
206010028813 Nausea Diseases 0.000 claims abstract description 7
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 7
230000008693 nausea Effects 0.000 claims abstract description 7
229920001281 polyalkylene Polymers 0.000 claims abstract description 6
150000003839 salts Chemical class 0.000 claims abstract description 6
125000001424 substituent group Chemical group 0.000 claims abstract description 6
230000036528 appetite Effects 0.000 claims abstract description 5
235000019789 appetite Nutrition 0.000 claims abstract description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 4
210000000987 immune system Anatomy 0.000 claims abstract description 4
125000000304 alkynyl group Chemical group 0.000 claims abstract description 3
238000004519 manufacturing process Methods 0.000 claims abstract description 3
230000000269 nucleophilic effect Effects 0.000 claims abstract description 3
125000003367 polycyclic group Chemical group 0.000 claims abstract description 3
150000003568 thioethers Chemical class 0.000 claims abstract description 3
150000003573 thiols Chemical class 0.000 claims abstract description 3
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract 5
230000000202 analgesic effect Effects 0.000 claims abstract 2
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims abstract 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract 2
239000000932 sedative agent Substances 0.000 claims abstract 2
230000001624 sedative effect Effects 0.000 claims abstract 2
230000036592 analgesia Effects 0.000 claims description 8
206010039897 Sedation Diseases 0.000 claims description 3
230000036280 sedation Effects 0.000 claims description 3
238000002560 therapeutic procedure Methods 0.000 claims 2
125000004429 atom Chemical group 0.000 claims 1
125000005843 halogen group Chemical group 0.000 claims 1
230000007943 positive regulation of appetite Effects 0.000 claims 1
230000001629 suppression Effects 0.000 claims 1
230000004410 intraocular pressure Effects 0.000 abstract description 3
125000001475 halogen functional group Chemical group 0.000 abstract description 2
SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical group C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 abstract description 2
125000006413 ring segment Chemical group 0.000 abstract description 2
108010084714 arachidonoylethanolamide synthase Proteins 0.000 description 24
210000004027 cell Anatomy 0.000 description 20
230000000694 effects Effects 0.000 description 17
QIVFMUVBIHIZAM-UHFFFAOYSA-N hexadecane-1-sulfonyl fluoride Chemical compound CCCCCCCCCCCCCCCCS(F)(=O)=O QIVFMUVBIHIZAM-UHFFFAOYSA-N 0.000 description 15
102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 14
108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 14
229930003827 cannabinoid Natural products 0.000 description 13
239000003557 cannabinoid Substances 0.000 description 13
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 12
229940065144 cannabinoids Drugs 0.000 description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
241000700159 Rattus Species 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 8
108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
210000004556 brain Anatomy 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
238000000034 method Methods 0.000 description 7
239000000203 mixture Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
206010029260 Neuroblastoma Diseases 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
239000000243 solution Substances 0.000 description 6
239000002904 solvent Substances 0.000 description 6
241000699670 Mus sp. Species 0.000 description 5
235000014113 dietary fatty acids Nutrition 0.000 description 5
229930195729 fatty acid Natural products 0.000 description 5
239000000194 fatty acid Substances 0.000 description 5
150000004665 fatty acids Chemical class 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
238000012360 testing method Methods 0.000 description 5
102000018208 Cannabinoid Receptor Human genes 0.000 description 4
108050007331 Cannabinoid receptor Proteins 0.000 description 4
102100033868 Cannabinoid receptor 1 Human genes 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
239000002253 acid Substances 0.000 description 4
125000004390 alkyl sulfonyl group Chemical group 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000027455 binding Effects 0.000 description 4
VQFQXLQALUCXND-UHFFFAOYSA-N icosane-1-sulfonyl fluoride Chemical compound CCCCCCCCCCCCCCCCCCCCS(F)(=O)=O VQFQXLQALUCXND-UHFFFAOYSA-N 0.000 description 4
238000011534 incubation Methods 0.000 description 4
239000012038 nucleophile Substances 0.000 description 4
238000010992 reflux Methods 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
OBTWBSRJZRCYQV-UHFFFAOYSA-N sulfuryl difluoride Chemical compound FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
238000004440 column chromatography Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
125000005842 heteroatom Chemical group 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000012528 membrane Substances 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000036407 pain Effects 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
101150065749 Churc1 gene Proteins 0.000 description 2
XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
208000010412 Glaucoma Diseases 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
102100038239 Protein Churchill Human genes 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
229940114078 arachidonate Drugs 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000007423 decrease Effects 0.000 description 2
CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
UVLRFDMRDPQRSM-UHFFFAOYSA-N dodecane-1-sulfonyl fluoride Chemical compound CCCCCCCCCCCCS(F)(=O)=O UVLRFDMRDPQRSM-UHFFFAOYSA-N 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Chemical group 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
230000000506 psychotropic effect Effects 0.000 description 2
101150112263 sla gene Proteins 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
238000003756 stirring Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
229910052717 sulfur Chemical group 0.000 description 2
239000011593 sulfur Chemical group 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
PLWROONZUDKYKG-DOFZRALJSA-N AACOCF3 Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)C(F)(F)F PLWROONZUDKYKG-DOFZRALJSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
102100036214 Cannabinoid receptor 2 Human genes 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
102100021973 Carbonyl reductase [NADPH] 1 Human genes 0.000 description 1
241000700198 Cavia Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
238000001061 Dunnett's test Methods 0.000 description 1
241000283086 Equidae Species 0.000 description 1
MWHHJYUHCZWSLS-UHFFFAOYSA-N FC=1C=C(C=CC1C1=C2CNC(C2=C(C=C1)C=1NC(=CN1)C)=O)NC(=O)NC1=C(C=C(C=C1F)F)F Chemical compound FC=1C=C(C=CC1C1=C2CNC(C2=C(C=C1)C=1NC(=CN1)C)=O)NC(=O)NC1=C(C=C(C=C1F)F)F MWHHJYUHCZWSLS-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
101000896985 Homo sapiens Carbonyl reductase [NADPH] 1 Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000010909 Monoamine Oxidase Human genes 0.000 description 1
108010062431 Monoamine oxidase Proteins 0.000 description 1
BJNOJBCOEGSLMU-UHFFFAOYSA-N O(NCl)Cl Chemical class O(NCl)Cl BJNOJBCOEGSLMU-UHFFFAOYSA-N 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
101100257029 Rattus norvegicus Sla gene Proteins 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
238000006600 Stobbe condensation reaction Methods 0.000 description 1
241000282887 Suidae Species 0.000 description 1
241000906446 Theraps Species 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000004596 appetite loss Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
159000000032 aromatic acids Chemical class 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000003925 brain function Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
244000309466 calf Species 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229960004242 dronabinol Drugs 0.000 description 1
238000009510 drug design Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000012259 ether extract Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical class FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
206010021654 increased appetite Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
208000019017 loss of appetite Diseases 0.000 description 1
235000021266 loss of appetite Nutrition 0.000 description 1
229910001623 magnesium bromide Inorganic materials 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
230000036651 mood Effects 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
125000006574 non-aromatic ring group Chemical group 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
SZXIBISKCHYMAR-UHFFFAOYSA-N octadecane-1-sulfonyl fluoride Chemical compound CCCCCCCCCCCCCCCCCCS(F)(=O)=O SZXIBISKCHYMAR-UHFFFAOYSA-N 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000000758 substrate Substances 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
QKRWHXNZSPRRMB-UHFFFAOYSA-N tetradecane-1-sulfonyl fluoride Chemical compound CCCCCCCCCCCCCCS(F)(=O)=O QKRWHXNZSPRRMB-UHFFFAOYSA-N 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000005292 vacuum distillation Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Transplantation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrrole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

ES97927958T 1996-05-31 1997-05-30 Nuevos inhibidores de anandamida amidasa como agentes analgesicos. Expired - Lifetime ES2278391T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US658949		1984-10-09
US08/658,949 US5688825A (en)	1996-05-31	1996-05-31	Anandamide amidase inhibitors as analgesic agents

Publications (1)

Publication Number	Publication Date
ES2278391T3 true ES2278391T3 (es)	2007-08-01

Family

ID=24643395

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES97927958T Expired - Lifetime ES2278391T3 (es)	1996-05-31	1997-05-30	Nuevos inhibidores de anandamida amidasa como agentes analgesicos.

Country Status (8)

Country	Link
US (4)	US5688825A (2)
EP (2)	EP1021406B1 (2)
JP (1)	JP2000511540A (2)
AU (1)	AU3229097A (2)
CA (1)	CA2255620C (2)
DE (1)	DE69737039T2 (2)
ES (1)	ES2278391T3 (2)
WO (1)	WO1997045407A1 (2)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5688825A (en) *	1996-05-31	1997-11-18	University Of Connecticut	Anandamide amidase inhibitors as analgesic agents
WO1999057106A1 (en) *	1998-05-04	1999-11-11	The University Of Connecticut	Novel analgesic and immunomodulatory cannabinoids
WO1999057107A2 (en) *	1998-05-04	1999-11-11	The University Of Connecticut	Cannabinoids selective for the cb2 receptor
JP2002517479A (ja) *	1998-06-09	2002-06-18	ザ・ユニバ−シティ・オブ・コネチカット	鎮痛薬としてのアナンダミド輸送体阻害剤
US7897598B2 (en) *	1998-06-09	2011-03-01	Alexandros Makriyannis	Inhibitors of the anandamide transporter
US7589220B2 (en) *	1998-06-09	2009-09-15	University Of Connecticut	Inhibitors of the anandamide transporter
US7161016B1 (en)	1998-11-24	2007-01-09	University Of Connecticut	Cannabimimetic lipid amides as useful medications
US7276613B1 (en) *	1998-11-24	2007-10-02	University Of Connecticut	Retro-anandamides, high affinity and stability cannabinoid receptor ligands
WO2000066260A1 (en)	1999-04-28	2000-11-09	Toray Industries, Inc.	Materials for eliminating cannabinoids and columns for the elimination of cannabinoids with the use of the same
GB9923738D0 (en) *	1999-10-07	1999-12-08	Nestle Sa	Nutritional composition
US8084467B2 (en) *	1999-10-18	2011-12-27	University Of Connecticut	Pyrazole derivatives as cannabinoid receptor antagonists
EP1226112A4 (en) *	1999-10-18	2004-10-13	Univ Connecticut	RETRO-ANANDAMIDES, LIGANDS OF CANNABINOID RECEPTORS WITH HIGH AFFINITY AND STABILITY
US7393842B2 (en) *	2001-08-31	2008-07-01	University Of Connecticut	Pyrazole analogs acting on cannabinoid receptors
US7741365B2 (en) *	1999-10-18	2010-06-22	University Of Connecticut	Peripheral cannabinoid receptor (CB2) selective ligands
US6943266B1 (en) *	1999-10-18	2005-09-13	University Of Connecticut	Bicyclic cannabinoid agonists for the cannabinoid receptor
US7119108B1 (en)	1999-10-18	2006-10-10	University Of Connecticut	Pyrazole derivatives as cannabinoid receptor antagonists
DE60033834T2 (de)	1999-10-18	2007-11-15	The University Of Connecticut, Farmington	Für periphäre cannabinoid-rezeptoren selektive liganden
US6900236B1 (en)	1999-10-18	2005-05-31	University Of Connecticut	Cannabimimetic indole derivatives
ES2174716B1 (es) *	2000-07-28	2004-08-01	Universidad Complutense De Madrid	Nuevos derivados de acido araquidonico con afinidad por el transportador de anandamida.
AU2001284061A1 (en) *	2000-07-28	2002-02-18	Universidad Complutense De Madrid	Novel araquidonic acid derivatives with affinity toward the anandamide transporter
ES2181601B2 (es) *	2001-07-27	2004-04-01	Univ Madrid Complutense	Derivados de acido araquidonico con afinidad por el transportador de anandamida
JP2004532185A (ja) *	2001-01-26	2004-10-21	ユニバーシティオブコネチカット	新規なカンナビミメティックリガンド
WO2002060447A1 (en)	2001-01-29	2002-08-08	University Of Connecticut	Receptor selective cannabimimetic aminoalkylindoles
CA2437353A1 (en) *	2001-02-08	2002-08-15	Nps Pharmaceuticals, Inc.	Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same
US7057076B2 (en) *	2001-07-13	2006-06-06	University Of Connecticut	Bicyclic and tricyclic cannabinoids
JP4202250B2 (ja)	2001-07-25	2008-12-24	バイオマリンファーマシューティカルインコーポレイテッド	血液脳関門輸送を調節するための組成物および方法
CA2464333C (en) *	2001-10-26	2011-07-26	University Of Connecticut	Heteroindanes: a new class of potent cannabimimetic ligands
EP1482917B1 (en) *	2002-02-01	2019-05-08	GW Pharma Limited	Compositions comprising cannabidiolic acid for treatment of nausea, vomiting, emesis, motion sickness or like conditions
US20040063726A1 (en) *	2002-02-08	2004-04-01	Artman Linda D	Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same
IL148244A0 (en)	2002-02-19	2002-09-12	Yissum Res Dev Co	Anti-nausea and anti-vomiting activity of cannabidiol compounds
US20060034872A1 (en) *	2002-04-29	2006-02-16	Woolf Clifford J	Compositions and methods for preventing abuse of orally administered medications
WO2003097573A1 (en) *	2002-05-16	2003-11-27	Sepracor, Inc.	Amines that inhibit a mammalian anandamide transporter, and methods of use thereof
WO2004103410A1 (en)	2002-06-06	2004-12-02	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Methods compositions and articles of manufacture for modulating bone growth
US7183313B2 (en)	2002-08-23	2007-02-27	University Of Connecticut	Keto cannabinoids with therapeutic indications
GB0403864D0 (en)	2004-02-20	2004-03-24	Ucl Ventures	Modulator
EP2671507A3 (en)	2005-04-28	2014-02-19	Proteus Digital Health, Inc.	Pharma-informatics system
MX2009002893A (es)	2006-09-18	2009-07-10	Raptor Pharmaceutical Inc	Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
US7781650B2 (en) *	2007-04-30	2010-08-24	Monsanto Technology Llc	Plants and seeds of corn variety CV202909
WO2009052319A1 (en) *	2007-10-16	2009-04-23	Northeastern University	Monoacylglycerol lipase inhibitors for modulation of cannabinoid activity
CA2752373C (en)	2009-02-20	2017-10-10	To-Bbb Holding B.V.	Glutathione-based drug delivery system
IL255113B (en)	2009-05-06	2022-09-01	Laboratory Skin Care Inc	Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120077778A1 (en)	2010-09-29	2012-03-29	Andrea Bourdelais	Ladder-Frame Polyether Conjugates
CA2953237C (en) *	2014-06-06	2024-06-11	The Scripps Research Institute	Sulfur(vi) fluoride compounds and methods for the preparation thereof
CN112121852B (zh) *	2020-08-27	2021-09-24	中山大学	催化剂组合物及催化剂组合物或催化剂用于催化亲核取代反应的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3465024A (en) *	1966-11-14	1969-09-02	Allied Chem	Process for the preparation of isocyanates
US3577458A (en) *	1966-11-14	1971-05-04	Allied Chem	Process for the preparation of isocyanates
US5804601A (en) *	1995-04-10	1998-09-08	Takeda Chemical Industries, Ltd.	Aromatic hydroxamic acid compounds, their production and use
US5688825A (en) *	1996-05-31	1997-11-18	University Of Connecticut	Anandamide amidase inhibitors as analgesic agents

1996
- 1996-05-31 US US08/658,949 patent/US5688825A/en not_active Expired - Lifetime
1997
- 1997-05-30 AU AU32290/97A patent/AU3229097A/en not_active Abandoned
- 1997-05-30 JP JP09543074A patent/JP2000511540A/ja active Pending
- 1997-05-30 DE DE69737039T patent/DE69737039T2/de not_active Expired - Lifetime
- 1997-05-30 ES ES97927958T patent/ES2278391T3/es not_active Expired - Lifetime
- 1997-05-30 EP EP97927958A patent/EP1021406B1/en not_active Expired - Lifetime
- 1997-05-30 CA CA002255620A patent/CA2255620C/en not_active Expired - Fee Related
- 1997-05-30 EP EP06024572A patent/EP1775286A1/en not_active Withdrawn
- 1997-05-30 WO PCT/US1997/009613 patent/WO1997045407A1/en not_active Ceased
- 1997-11-12 US US08/967,847 patent/US5874459A/en not_active Expired - Lifetime
2000
- 2000-04-20 US US09/553,499 patent/US6391909B1/en not_active Expired - Fee Related
2002
- 2002-02-06 US US10/068,588 patent/US6579900B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6579900B2 (en)	2003-06-17
DE69737039D1 (de)	2007-01-11
DE69737039T2 (de)	2007-06-21
US6391909B1 (en)	2002-05-21
CA2255620C (en)	2008-01-29
EP1021406B1 (en)	2006-11-29
AU3229097A (en)	1998-01-05
EP1021406A1 (en)	2000-07-26
US20020091153A1 (en)	2002-07-11
WO1997045407A1 (en)	1997-12-04
JP2000511540A (ja)	2000-09-05
US5688825A (en)	1997-11-18
US5874459A (en)	1999-02-23
CA2255620A1 (en)	1997-12-04
EP1775286A1 (en)	2007-04-18

Publication	Publication Date	Title
ES2278391T3 (es)	2007-08-01	Nuevos inhibidores de anandamida amidasa como agentes analgesicos.
ES2299251T3 (es)	2008-05-16	Inhibidores del factor de transcripcion nf-kappa b.
ES2259379T3 (es)	2006-10-01	Inhibidores hidrazino carbociclicos de la amina oxidasas que contienen cobre.
CN103864677B (zh)	2016-05-18	硫代乙酸盐化合物、组合物及其使用方法
CN101506161B (zh)	2013-11-13	具有快速皮肤穿透速度的带正电荷的水溶性的芳基和杂芳基丙酸类前药
ES2288039T3 (es)	2007-12-16	Derivados de amidas de indometacina destinadas a un uso antiangiogenico y/o antioncogenico.
CN101820848B (zh)	2015-06-10	抑制n-酰基乙醇胺水解性酸酰胺酶的组合物和方法
US20100144827A1 (en)	2010-06-10	Novel conjugates of polyunsaturated fatty acids with amines and therapeutic uses thereof
CN101506168B (zh)	2014-12-10	具有快速皮肤穿透速度的带正电荷的水溶性的芳基邻氨基苯甲酸的前药
CN101898978A (zh)	2010-12-01	依氟鸟氨酸前药和偶合物及其使用方法
KR20120041071A (ko)	2012-04-30	Ｈｉｆ-1 활성을 저해하는 아릴옥시페녹시아세틸계 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
ES2270634T3 (es)	2007-04-01	Conversion de compuestos de inhibicion de cox que no son inhibidores selectivos de cox-2 en derivados que son inhibidores selectivos de cox-2.
KR20170005116A (ko)	2017-01-11	피부암 치료
TW202035415A (zh)	2020-10-01	用於治療骨關節炎的化合物
US20230286955A1 (en)	2023-09-14	Inhibitors of them1
CA2615696A1 (en)	1997-12-04	Novel anandamide amidase inhibitors as analgesic agents
US20160279079A1 (en)	2016-09-29	Compositions and methods for treating bone diseases
CA3173724A1 (en)	2021-09-02	Methods for treating endometriosis
WO2024106529A1 (ja)	2024-05-23	抗肥満作用を有する新規化合物
EP4499622A1 (en)	2025-02-05	2-[(2-oxo-4-phenyl-2h-chromen-7-yl)oxy] propanamido derivatives
WO2025240850A1 (en)	2025-11-20	Nitroalkene-based inhibitors to target sting-dependent inflammation
JP2011162536A (ja)	2011-08-25	ビタミンｅ誘導体を有効成分とする鎮痛剤
JP2012067057A (ja)	2012-04-05	ピタバスタチン及びセルレニンを含有する経皮吸収促進剤
TW200530219A (en)	2005-09-16	Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
HK1196284B (en)	2018-02-23	Positively-charged water-soluble aryl and heteroaryl propionic acid prodrug with rapid skin penetrating speed